IPO Market Shows Signs of Life as Acelyrin Begins Nasdaq Bid 4/14/2023

Aer Therapeutics Raises $36M for Novel Approach to COPD 4/14/2023

Aspect Biosystems and Novo Nordisk to Tackle Type 1 Diabetes and Obesity 4/14/2023

The current COVID-19 vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time. Focusing on the T-cell instead, Penn State researchers partnered with Evaxion Biotech on a study that was the first to demonstrate the effectiveness of an artificial intelligence-generated vaccine in a live viral challenge model.

Alentis Wins $105M in Series C to Advance Claudin-1-Based Therapies 4/13/2023

Merck’s BTK Inhibitor Evobrutinib Slapped with Partial Clinical Hold 4/13/2023

Pfizer and BioNTech Sued for Patent Infringement Over mRNA Vaccine 4/13/2023

Treatment Approach to Depression Sees Paradigm Shift 4/13/2023

Navigating Retirement Savings Options 4/13/2023

Appellate Court Partially Blocks Texas Abortion Pill Ruling 4/13/2023

AstraZeneca, Swedish Orphan Biovitrum AB (publ) (Sobi) and Sanofi have updated and simplified their contractual arrangements relating to the development and commercialisation of nirsevimab in the US. Given the upcoming launch of nirsevimab in the US and other markets, simplification of the prior arrangements clarifies the roles and responsibilities of relevant parties.

A research team led by the National Cancer Centre Singapore (NCCS) with members from Duke-NUS Medical School, KK Women and Children’s Hospital, A*STAR's Singapore Immunology Network (SIgN), the University of Southampton and the Alan Turing Institute, has discovered how cancer evades the immune system and metastasises in the body, and explores how to shut down this dangerous feature.

Adoptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma. The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide a new treatment option to cancer patients, potentially bypassing radiation therapies and harsh chemotherapy drugs.

Glioblastoma is the most common type of brain tumor in adults. The disease is 100% fatal and there are no cures, making it the most aggressive type of cancer. Such a poor prognosis has motivated researchers and neurosurgeons to understand the biology of tumors with the goal of creating better therapies.

CycPeptMPDB, a novel database - created by Tokyo Tech researchers - focused on the membrane permeability of cyclic peptides, could accelerate the development of drugs based on these promising compounds. This database was created by gathering published information on thousands of cyclic peptides and organizing it neatly in an online-accessible platform.

Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.

Lilly's Donanemab Data Energizes Alzheimer’s Sector, Safety Concerns Remain 5/4/2023

ImmunoGen’s Elahere Aces Confirmatory Trial, Poised to Win Full Approval 5/4/2023

Moderna Reports Modest Income for Q1, Preps for RSV Vaccine Approval and Launch 5/4/2023

How to determine the most effective treatment for colon cancer? The response to chemotherapy varies greatly from one patient to another. A team from the UNIGE has developed a new method for testing different drugs, without going through the affected person’s body and without resorting to animal experiments. The researchers used organoids - miniature reproductions of organs and tissues - derived from patients and exposed to treatments.